Clinical trial to evaluate role of Tripada Guggul Vati as adjuvant treatment in Madhumeha Type2 DM
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2019/07/020141
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients with Signs & Symptoms of Madhumeha (hastapadtaladaha, pipasa, kshudhavridhhi, prabhutmootrata, avilmootrata, naktamootrata, Daurbalya, swedativrudhhi)
2.Age : 25 years to 60 years of either gender.
3.K/C/O Type 2 Diabetes Mellitus from 1- 5 years
4.BSL - F >126 mg/dl & BSL-PP > 200 mg/dl up to 300mg/dl
5.HbA1c â?? <10 % ( showing good , fair, moderate control)
1.Known cases of TYPE-1 Diabetes Mellitus
2. Patients with any major systemic complications of DM.
3. Patients having any other major illness.
4. Known case of gestational diabetes.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the efficacy of an adjuvant effect of Tripada Guggul (Susrutokta) VatiTimepoint: 90 days
- Secondary Outcome Measures
Name Time Method 1.To evaluate the efficacy of drug in achieving glycaemic control on the basis of HbA1c , BSL-fasting , BSL-post prandial state, urine sugar fasting and post prandial. <br/ ><br>2.To evaluate the efficacy of drug on subjective parameters like kshudhavridhhi, pipasa, prabhutamutrata, Naktamutrata, Avil mutrata, hastapadtal daha, daurbalya, swedativrudhhi. <br/ ><br>3.To observe the effect of drug on body weight. <br/ ><br>4.To observe the effect of drug on B.M.I. <br/ ><br> <br/ ><br>Timepoint: HbA1cat day 0 and day 90, BSL-fasting/BSL-PP, urine sugar fasting and PP done monthly for 90 days. <br/ ><br>2.To evaluate the efficacy of drug on subjective parameters like kshudhavridhhi, pipasa, prabhutamutrata, Naktamutrata, Avil mutrata, hastapadtal daha, daurbalya, swedativrudhhi.